NCT03007979已完成2 期
A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
- 试验地点
- 2
- 主要终点
- Rate of Grade 3 or Higher Neutropenia
研究概览
简要总结
The investigators propose to conduct a study to test an alternative dosing schedule of palbociclib. With the current three-week on and one week off schedule, a significant number of patients develop grade 3 or higher degree of neutropenia and require dose reduction and sometimes discontinuation. This potentially compromises the efficacy of the drug. In addition, as the half-life of palbociclib is 27 hours, 1 week break with the standard 3 weeks on and 1 week off dosing schedule could potentially lead to recovery of Rb phosphorylation during the off week. Hence, the investigators propose a 5 days on and 2 days off schedule each week without any weeks off drug. Although the cumulative doses each 28-day cycle is roughly the same with this schedule compared to conventional dosing, the bone marrow is not exposed to the drug continuously for 21 days and rather gets frequent breaks from therapy. The investigators hypothesize that the 5 days on and 2 days off schedule is more tolerable with less frequent high grade neutropenia and dose interruption/reduction. In addition, this schedule also provides for a more continuous drug delivery to the patient since there is not a week's break in therapy, which could ultimately prove to be more efficacious.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed metastatic ER+ and/or PR+ and HER2- breast cancer who are candidates for palbociclib in combination with either letrozole or fulvestrant per treating physician.
- •Presence of measurable or non-measurable disease by RECIST 1.1 criteria.
- •One prior systemic therapy in the metastatic setting is allowed, but patients who have not had any prior systemic therapies in the metastatic setting are also eligible.
- •*Note: patients who were started on endocrine therapy monotherapy as their 1st line or 2nd line systemic therapy in the metastatic setting for no more than 28 days and without clinical progression prior to the initiation of the study drug therapy are allowed to enroll on the study as their 1st line or 2nd line therapy, respectively.
- •At least 18 years of age.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- •Normal bone marrow and organ function as defined below:
- •Absolute neutrophil count ≥ 1,500/mcl
- •Platelets ≥ 100,000/mcl
- •Total bilirubin ≤ institutional upper limit of normal (IULN) or total bilirubin ≤ 3.0 x IULN with direct bilirubin within normal range in patients with documented Gilbert's syndrome
- •AST(SGOT)/ALT(SGPT) ≤ 1.5 x IULN (up to 5 x IULN in patients with liver disease)
- •Creatinine ≤ IULN OR creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with serum creatinine levels above institutional normal (calculated by Creatinine Clearance Estimate by Cockcroft-Gault Equation)
- •Pre- or post-menopausal women are allowed. If pre- or peri-menopausal, concurrent ovarian suppression for pre- or peri-menopausal women is required.
- •Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- •Able to swallow and retain oral medication.
- •Washout of at least 3 weeks from prior chemotherapy or targeted therapy that induces myelosuppression and recovery of treatment related adverse events to grade 1 or less, with the exception of alopecia, is required prior to the start of palbociclib.
- •Ability to understand and willingness to sign an Institutional Review Board (IRB) approved written informed consent document (or that of legally authorized representative, if applicable).
排除标准
- •Prior therapy with any CDK inhibitor.
- •Currently receiving any other investigational agents.
- •Currently receiving exogenous estrogen replacement (topical vaginal estrogen therapy is allowed).
- •Known brain metastases. Patients with known brain metastases must be excluded from this clinical trial because of their poor prognosis which could affect the evaluation of all-cycle adverse events.
- •A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib or other agents used in the study.
- •Receiving any medications or substances that are potent inhibitors or inducers of CYP3A isoenzymes within 7 days prior to registration.
- •Clinically significant history of liver disease.
- •A condition that would interfere with enteric absorption.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
- •Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of study entry.
- •Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with palbociclib. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
研究组 & 干预措施
Palbociclib + letrozole or + fulvestrant
Experimental
- Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).
- Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.
- Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
- Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.
- Optional research biopsy at baseline and progression
- Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression
干预措施: Palbociclib (Drug)
Palbociclib + letrozole or + fulvestrant
Experimental
- Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).
- Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.
- Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
- Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.
- Optional research biopsy at baseline and progression
- Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression
干预措施: Letrozole (Drug)
Palbociclib + letrozole or + fulvestrant
Experimental
- Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).
- Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.
- Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
- Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.
- Optional research biopsy at baseline and progression
- Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression
干预措施: Fulvestrant (Drug)
Palbociclib + letrozole or + fulvestrant
Experimental
- Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).
- Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.
- Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
- Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.
- Optional research biopsy at baseline and progression
- Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression
干预措施: Optional research biopsy (Procedure)
Palbociclib + letrozole or + fulvestrant
Experimental
- Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).
- Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.
- Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
- Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.
- Optional research biopsy at baseline and progression
- Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression
干预措施: Goserelin (Drug)
Palbociclib + letrozole or + fulvestrant
Experimental
- Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).
- Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.
- Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
- Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.
- Optional research biopsy at baseline and progression
- Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression
干预措施: Research blood draw (Procedure)
Palbociclib + letrozole or + fulvestrant
Experimental
- Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).
- Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.
- Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
- Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.
- Optional research biopsy at baseline and progression
- Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression
干预措施: Circulating tumor cell blood draw (Procedure)
Palbociclib + letrozole or + fulvestrant
Experimental
- Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).
- Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.
- Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
- Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.
- Optional research biopsy at baseline and progression
- Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression
干预措施: Tumor biopsy (optional) (Procedure)
结局指标
主要结局
Rate of Grade 3 or Higher Neutropenia
时间窗: Through the first 29 days of treatment
* The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting. * Grade 3 neutropenia: \<1000-500/mm\^3; \<1.0-0.5 x 10e9/L * Grade 4 neutropenia: \<500/mm\^3; \<0.5 x 10e9/L
次要结局
- Rate of Grade 3 or Higher Neutropenia(Through 30 day follow-up (estimated to be 25 months))
- Rate of Palbociclib Dose Reduction(Through the completion of treatment (estimated to be 24 months))
- Clinical Benefit Rate (Complete Response + Partial Response + Stable Disease) for at Least 6 Months)(Time of progression (estimated to be 24 months))
- Rate of Palbociclib Dose Interruption(Through the completion of treatment (estimated to be 24 months))
- Rate of Palbociclib Discontinuation(Through the completion of treatment (estimated to be 24 months))
- Adverse Event Profile of Palbociclib(Through the 30 day follow-up (estimated to be 25 months))
- Kaplan-Meier Estimate of Progression-free Survival (PFS)(1 year)
- Overall Response Rate (Complete Response + Partial Response)(Time of progression (estimated to be 24 months))
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)Metastatic Breast Cancer (MBC)NCT02605486Memorial Sloan Kettering Cancer Center46
招募中
2 期
Palbociclib and Pembrolizumab In Central Nervous System MetastasesMetastatic Malignant Neoplasm to BrainRecurrent Brain MetastasesProgressive Brain MetastasesNCT02896335Massachusetts General Hospital45
已完成
2 期
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive ImpairmentMild Cognitive Impairment, So StatedNCT00422981Allon Therapeutics144
进行中（未招募）
1 期
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast CancerTriple Negative Breast CancerLocally Advanced Breast CancerRecurrent Breast CancerER+ Breast CancerHER2-positive Breast CancerMetastatic Breast CancerNCT04360941Royal Marsden NHS Foundation Trust45
已完成
2 期
Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled HypertensionHypertension, RenalNCT05001945Mineralys Therapeutics Inc.200